- Home
- MRNA vs FFIV Comparison
MRNA vs FFIV Comparison
Compare MRNA & FFIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRNA | FFIV |
|---|---|---|
| Founded | 2010 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Communications Equipment |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.7B | 21.6B |
| IPO Year | 2018 | 1999 |
Fundamental Metrics
Financial Performance| Metric | MRNA | FFIV |
|---|---|---|
| Price | $72.47 | $424.19 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 12 | 11 |
| Target Price | $34.27 | ★ $312.88 |
| AVG Volume (30 Days) | ★ 7.6M | 564.7K |
| Earning Date | 05-01-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 21.77 | ★ 23.56 |
| EPS | N/A | ★ 5.68 |
| Revenue | ★ $19,263,000,000.00 | $3,088,072,000.00 |
| Revenue This Year | $9.36 | $8.00 |
| Revenue Next Year | $15.43 | $3.27 |
| P/E Ratio | ★ N/A | $73.25 |
| Revenue Growth | 4.29 | ★ 9.66 |
| 52 Week Low | $22.28 | $223.76 |
| 52 Week High | $73.28 | $427.54 |
Technical Indicators
Market Signals| Indicator | MRNA | FFIV |
|---|---|---|
| Relative Strength Index (RSI) | 74.31 | 71.76 |
| Support Level | $45.69 | $376.32 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 5.14 | 12.07 |
| MACD | 1.66 | 1.08 |
| Stochastic Oscillator | 92.36 | 88.64 |
Price Performance
Historical ComparisonAbout MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About FFIV F5 Inc.
F5 is a market leader in the application delivery controller market. The company sells products for security, application performance, and automation. Its three customer verticals are enterprises, service providers, and government entities. Revenue is evenly split between its services business and products business with revenue trending toward products due to software adoption. The Seattle-based firm was incorporated in 1996, and went public in 1999.